04 August 2023: Clinical Research
Impact of Coexisting Risk Factors on Outcomes in Patients with Acute Coronary Syndrome: A Real-World Analysis Using the Taiwan Chang Gung Research Database
Wei-Chieh Lee 1234ABCDEG** , Po-Jui Wu 3AG , Yi-Hsuan Tsai 5CD , Yun-Yu Hsieh 5CD , Tien-Yu Chen 5F , Yen-Nan Fang 3F , Huang-Chung Chen 3F , Hsiu-Yu Fang 36F**DOI: 10.12659/MSM.941258
Med Sci Monit 2023; 29:e941258
Table 1 Baseline characteristics in the patients.
| Variable | DM | CKD | Elderly | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-DM | DM | P value | Non-CKD | CKD | P value | Non-elderly | Elderly | P value | |
| 16743 | 11870 | 14019 | 14594 | 19155 | 9458 | ||||
| Age (years) | 66.02 ±14.68 | 67.98 ±12.25 | 61.69 ±13.50 | 71.77 ±12.10 | 59.41 ±10.17 | 81.86 ±5.10 | |||
| Male sex (%) | 12301 (73.47) | 7465 (62.89) | 10692 (76.27) | 9074 (62.18) | 14519 (75.80) | 5247 (55.48) | |||
| BMI (kg/m) | 24.67 ±4.31 | 25.20 ±4.42 | 25.38 ±4.41 | 24.44 ±4.28 | 25.65 ±4.27 | 23.26 ±4.08 | |||
| Diabetes mellitus (%) | 0 (0) | 11870 (100) | 4186 (29.86) | 6261 (42.90) | 7221 (37.70) | 3226 (34.11) | |||
| Hypertension (%) | 8142 (48.63) | 7850 (66.13) | 7067 (50.41) | 8925 (61.16) | 10521 (54.93) | 5471 (57.85) | |||
| PAOD (%) | 64 (0.38) | 128 (1.08) | 54 (0.39) | 138 (0.95) | 120 (0.63) | 72 (0.76) | 0.189 | ||
| COPD (%) | 995 (5.94) | 535 (4.51) | 602 (4.29) | 928 (6.36) | 591 (3.09) | 939 (9.93) | |||
| ESRD (%) | 805 (4.81) | 1344 (11.32) | 0 (0) | 2099 (14.38) | 1194 (6.23) | 955 (10.10) | |||
| Smoking (%) | 2906 (17.36) | 1298 (10.94) | 2790 (19.90) | 1414 (9.69) | 3551 (18.54) | 653 (6.90) | |||
| Liver cirrhosis (%) | 231 (1.38) | 232 (1.95) | 0.001 | 185 (1.32) | 278 (1.90) | 311 (1.62) | 152 (1.61) | 0.917 | |
| Prior GI bleeding (%) | 1621 (9.68) | 1604 (13.51) | 737 (5.26) | 2488 (17.05) | 1481 (7.73) | 1744 (18.44) | |||
| Prior stroke (%) | 1029 (6.15) | 1081 (9.11) | 777 (5.54) | 1333 (9.13) | 1134 (5.92) | 976 (10.32) | |||
| Antiplatelet agent | |||||||||
| Aspirin (%) | 10730 (64.09) | 7629 (64.27) | 0.748 | 10368 (73.96) | 7991 (54.76) | 13680 (71.42) | 4679 (49.47) | ||
| Clopidogrel (%) | 8761 (52.33) | 6489 (54.67) | 0.001 | 7927 (56.54) | 7323 (50.18) | 10759 (56.17) | 4491 (47.48) | ||
| Ticagrelor (%) | 2203 (13.16) | 1502 (12.65) | 0.211 | 2539 (18.11) | 1166 (7.99) | 3193 (16.67) | 512 (5.41) | ||
| F/U period (years) | 2.0 ±1.2 | 1.9 ±1.2 | 2.3 ±1.0 | 1.6 ±1.3 | 2.2 ±1.1 | 1.5 ±1.3 | |||
| Data are expressed as mean (standard deviation) or as number (percentage). BMI – body mass index; PAOD – peripheral arterial occlusive disease; COPD – chronic obstructive pulmonary disease; ESRD – end-stage renal disease; GI – gastrointestinal; F/U – follow-up. | |||||||||